Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)
DRUG
2 trials
Sponsors
Hoffmann-La Roche
, Genentech, Inc.
Conditions
HER2-Positive Early Breast Cancer
HER2-positive Breast Cancer
Phase 2
A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer
Completed
NCT03674112
Hoffmann-La Roche
HER2-Positive Early Breast Cancer
Start: 2018-12-19
End: 2022-10-12
Updated: 2024-01-02
Unknown Phase
An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic
NCT04395508
Genentech, Inc.
HER2-positive Breast Cancer
Updated: 2022-07-05
Related Papers
Long-Term Safety and Efficacy of the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients With HER2-Positive Early Breast Cancer in PHranceSCa, a Randomized, Open-Label Phase II Study.
2025-05-03
1 citations
Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC.
2025-02-19
1 citations
A preferência de profissionais de saúde e pacientes pela via de administração da terapia sistêmica no tratamento do câncer de mama HER2-positivo: uma revisão sistemática da literatura
Jornal de Assistência Farmacêutica e Farmacoeconomia
2023-11-08
97P Efficacy and safety of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer: Long-term data from the PHranceSCa study
ESMO Open
2023-05-01
2 citations
Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer.
2022-10-07
4 citations
Preliminary analysis of an expanded access study of the fixed-dose combination of pertuzumab (P) and trastuzumab (H) for subcutaneous injection (PH FDC SC) for at-home administration (admin) in patients (pts) with HER2-positive (HER2+) breast cancer (BC) during the COVID-19 pandemic.
Journal of Clinical Oncology
2022-06-01
8 citations
Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.
2021-06-16
52 citations
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive breast cancer: A multidisciplinary approach.
2021-03-09
11 citations
Subcutaneous Treatment vs. IV Infusion for HER2-Positive Breast Cancer
Oncology Times
2020-05-19